menu
    • menu

    Company profile for Aelis Farma

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aelis Farma mission is a clinical stage biotech company opening a new frontier in pharmacology.Develop the therapeutic potential of CB1-SSi CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology. CB1-SSi have a unique mechanism of action CB1-SSi are new molecular entities (NME) that mimick a natural defense mechanism of t...
    Aelis Farma mission is a clinical stage biotech company opening a new frontier in pharmacology.Develop the therapeutic potential of CB1-SSi CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology. CB1-SSi have a unique mechanism of action CB1-SSi are new molecular entities (NME) that mimick a natural defense mechanism of the brain (Science 2014). CB1-SSi do not block, like available antagonists, all the cellular activities of a receptor. CB1-SSi correct selectively the cellular activity hyperactivated in the pathological state.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aelis FarmaFrance Flag
    Country
    Country
    France
    Address
    Address
    Neurocentre Magendie 146, rue Léo Saignat 33 077 Bordeaux
    Telephone
    Telephone
    +33 5 57 57 37 70
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aelisfarma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Indivior Updates on Aelis Farma's Phase 2B Results for Cannabis Use Disorder
    Indivior Updates on Aelis Farma's Phase 2B Results for Cannabis Use Disorder

    04 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237335.html

    PR NEWSWIRE
    04 Sep 2024
    Share Share
    Indivior Announces First Patient Included in Aelis Farma's PIIb Study of AEF0117
    Indivior Announces First Patient Included in Aelis Farma's PIIb Study of AEF0117

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-first-patient-included-in-aelis-farmas-phase-2b-study-assessing-the-efficacy-safety-and-tolerability-of-aef0117-in-treatment-seeking-subjects-with-moderate-to-severe-cannabis-use-disorder-301559110.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    Indivior Exclusive Agreement For Asset Targeting Cannabis-Related Disorders
    Indivior Exclusive Agreement For Asset Targeting Cannabis-Related Disorders

    08 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-extends-leadership-position-in-substance-use-disorder-treatment-with-exclusive-agreement-for-leading-asset-targeting-cannabis-related-disorders-301307340.html

    PRNEWSWIRE
    08 Jun 2021
    Share Share
    Indivior branches out, picking up an option for cannabis addiction drug
    Indivior branches out, picking up an option for cannabis addiction drug

    08 Jun 2021

    // Amber Tong ENDPTS

    https://endpts.com/keen-to-turn-a-new-page-indivior-branches-out-picking-up-an-option-for-cannabis-addiction-drug/

    Amber Tong ENDPTS
    08 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search